Ultra-low-dose interleukin-2 in unresectable hepatocellular carcinoma.
Am J Clin Oncol
; 25(3): 224-6, 2002 Jun.
Article
em En
| MEDLINE
| ID: mdl-12040276
ABSTRACT
At present, no effective therapy is available for hepatocellular carcinoma, when local treatments have failed. We reported the results obtained with prolonged, ultra-low-dose (1 MIU/d until progression), subcutaneous interleukin-2 (IL-2) in a series of 18 consecutive patients (14 men and 4 women, median age 66 years, range 49-82 years) with advanced, histologically proven HCC on liver cirrhosis. During a median follow-up time of 19.5 months, two complete responses (11.1%), lasting 35 and 46 months, respectively, and one partial response (5.5%) were recorded (overall response rate 16.6%; 95% CI 0-33.8%). Thirteen patients (72.3%; 95% CI 61.6-82.7) had stable disease lasting at least 4 months; 1 of these patients obtained a complete response on lung metastases. Median time to progression was 15.3 months (95% CI 10-33). Median overall survival was 24.5 months (95% CI 12-43). Two patients (11.1%) progressed during therapy. Toxicity was only local (usually pain and pomphus in the site of injection). Low-dose IL-2 can be considered an active and well-tolerated treatment for unresectable hepatocellular carcinoma. Future studies on large numbers of patients are necessary to confirm these results.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Interleucina-2
/
Carcinoma Hepatocelular
/
Neoplasias Hepáticas
/
Antineoplásicos
Limite:
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Am J Clin Oncol
Ano de publicação:
2002
Tipo de documento:
Article
País de afiliação:
Itália